Cargando…
Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients
Colon cancer is one of the major causes of cancer death worldwide. The five-year survival rate for the early-stage patients is more than 90%, and only around 10% for the later stages. Moreover, half of the colon cancer patients have been clinically diagnosed at the later stages. It is; therefore, of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628020/ https://www.ncbi.nlm.nih.gov/pubmed/31207989 http://dx.doi.org/10.3390/ijms20122919 |
_version_ | 1783434868487618560 |
---|---|
author | Zhang, Xueli Zhang, Hong Shen, Bairong Sun, Xiao-Feng |
author_facet | Zhang, Xueli Zhang, Hong Shen, Bairong Sun, Xiao-Feng |
author_sort | Zhang, Xueli |
collection | PubMed |
description | Colon cancer is one of the major causes of cancer death worldwide. The five-year survival rate for the early-stage patients is more than 90%, and only around 10% for the later stages. Moreover, half of the colon cancer patients have been clinically diagnosed at the later stages. It is; therefore, of importance to enhance the ability for the early diagnosis of colon cancer. Taking advantages from our previous studies, there are several potential biomarkers which have been associated with the early diagnosis of the colon cancer. In order to investigate these early diagnostic biomarkers for colon cancer, human chromogranin-A (CHGA) was further analyzed among the most powerful diagnostic biomarkers. In this study, we used a logistic regression-based meta-analysis to clarify associations of CHGA expression with colon cancer diagnosis. Both healthy populations and the normal mucosa from the colon cancer patients were selected as the double normal controls. The results showed decreased expression of CHGA in the early stages of colon cancer as compared to the normal controls. The decline of CHGA expression in the early stages of colon cancer is probably a new diagnostic biomarker for colon cancer diagnosis with high predicting possibility and verification performance. We have also compared the diagnostic powers of CHGA expression with the typical oncogene KRAS, classic tumor suppressor TP53, and well-known cellular proliferation index MKI67, and the CHGA showed stronger ability to predict early diagnosis for colon cancer than these other cancer biomarkers. In the protein–protein interaction (PPI) network, CHGA was revealed to share some common pathways with KRAS and TP53. CHGA might be considered as a novel, promising, and powerful biomarker for early diagnosis of colon cancer. |
format | Online Article Text |
id | pubmed-6628020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66280202019-07-23 Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients Zhang, Xueli Zhang, Hong Shen, Bairong Sun, Xiao-Feng Int J Mol Sci Article Colon cancer is one of the major causes of cancer death worldwide. The five-year survival rate for the early-stage patients is more than 90%, and only around 10% for the later stages. Moreover, half of the colon cancer patients have been clinically diagnosed at the later stages. It is; therefore, of importance to enhance the ability for the early diagnosis of colon cancer. Taking advantages from our previous studies, there are several potential biomarkers which have been associated with the early diagnosis of the colon cancer. In order to investigate these early diagnostic biomarkers for colon cancer, human chromogranin-A (CHGA) was further analyzed among the most powerful diagnostic biomarkers. In this study, we used a logistic regression-based meta-analysis to clarify associations of CHGA expression with colon cancer diagnosis. Both healthy populations and the normal mucosa from the colon cancer patients were selected as the double normal controls. The results showed decreased expression of CHGA in the early stages of colon cancer as compared to the normal controls. The decline of CHGA expression in the early stages of colon cancer is probably a new diagnostic biomarker for colon cancer diagnosis with high predicting possibility and verification performance. We have also compared the diagnostic powers of CHGA expression with the typical oncogene KRAS, classic tumor suppressor TP53, and well-known cellular proliferation index MKI67, and the CHGA showed stronger ability to predict early diagnosis for colon cancer than these other cancer biomarkers. In the protein–protein interaction (PPI) network, CHGA was revealed to share some common pathways with KRAS and TP53. CHGA might be considered as a novel, promising, and powerful biomarker for early diagnosis of colon cancer. MDPI 2019-06-14 /pmc/articles/PMC6628020/ /pubmed/31207989 http://dx.doi.org/10.3390/ijms20122919 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhang, Xueli Zhang, Hong Shen, Bairong Sun, Xiao-Feng Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients |
title | Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients |
title_full | Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients |
title_fullStr | Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients |
title_full_unstemmed | Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients |
title_short | Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients |
title_sort | chromogranin-a expression as a novel biomarker for early diagnosis of colon cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628020/ https://www.ncbi.nlm.nih.gov/pubmed/31207989 http://dx.doi.org/10.3390/ijms20122919 |
work_keys_str_mv | AT zhangxueli chromograninaexpressionasanovelbiomarkerforearlydiagnosisofcoloncancerpatients AT zhanghong chromograninaexpressionasanovelbiomarkerforearlydiagnosisofcoloncancerpatients AT shenbairong chromograninaexpressionasanovelbiomarkerforearlydiagnosisofcoloncancerpatients AT sunxiaofeng chromograninaexpressionasanovelbiomarkerforearlydiagnosisofcoloncancerpatients |